Skip to main content
Delfa

← All trials/NCT07874932

Not yet recruitingPhase NA

Long-Term Effects of Semaglutide on Body Composition and Performance in Running

Mitigating Muscle Loss and Preserving Function During Incretin-induced Caloric Restriction

Asset

Semaglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

-

Estimated enrollment

41

Study population

Body Composition, Caloric Restriction, Performance

Eligibility highlights

•BMI 21-26•Healthy volunteers

Primary endpoint

•Total lean mass

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07874932
Org study IDGLP-1_long

Timeline

Milestones

Study start2026-10-14estimated
Study first posted2026-10-15actual
Last update posted2026-10-15actual
Primary completion2027-12-30estimated
Study completion2028-04-30estimated

Assets

Investigational agents

Semaglutide

Who this study enrolls

Body CompositionCaloric RestrictionPerformance

Who can enroll

Minimum age18 Years
Maximum age45 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•Healthy experienced triathletes or distance runners (training history +5 years and weekly training volume >10 h/week)
•Aged 18 to 45 years
•Body mass index (BMI) between 21.0-26.0 kg/m2

Exclusion criteria

•Chronic use of medication (except for occasional use of analgesics or antihistamines)
•Chronic disease (e.g. diabetes, disordered eating behavior (EDE-Q >2.5 for females and 1.7 for males))
•Abnormal kidney function, or ECG abnormalities.

For female participants, additional exclusion criteria are

•Pregnancy
•Current or recent use of any hormonal contraceptives the last 6 months (including oral contraceptives, hormonal implants, injectable contraceptives, and hormone-releasing intrauterine devices)
•Irregular menstrual cycles (cycle length outside the 21-35-day range) and anovulatory cycles

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
5
Weight & body composition
1

Weight & body composition

1 endpoint
Primary/protocol endpoint

Change in total lean mass measured by dual-energy X-ray absorptiometry (DXA)

Time frame:Baseline (week 0), immediately after the 12-week intervention period (week 12), and immediately after the 4-week follow-up period without treatment (week 16).

change from baseline, improvement

Other (unclassified)

5 endpoints
Secondary/protocol endpoint/low confidence

Change in muscle thickness measured by ultrasonography

Time frame:Baseline (week 0), immediately after the 12-week intervention period (week 12), and immediately after the 4-week follow-up period without treatment (week 16).

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in running performance

Time frame:Baseline (week 0), immediately after the 12-week intervention period (week 12), and immediately after the 4-week follow-up period without treatment (week 16).

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in maximal voluntary isometric quadriceps contraction torque

Time frame:Baseline (week 0), immediately after the 12-week intervention period (week 12), and immediately after the 4-week follow-up period without treatment (week 16).

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in one-repetition maximum (1RM) leg press strength

Time frame:Baseline (week 0), immediately after the 12-week intervention period (week 12), and immediately after the 4-week follow-up period without treatment (week 16).

change from baseline, improvement

Other/protocol endpoint/low confidence

Changes in serum and urinary steroidal and endocrine biomarkers

Time frame:Baseline (week 0), immediately after the 12-week intervention period (week 12), and immediately after the 4-week follow-up period without treatment (week 16).

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateNovember 5, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.